Biotech Fund Doubles Down: Scholar Rock Bet Drives 26% Rally
A major biotech fund has increased its stake in Scholar Rock, increasing exposure to a platform that targets protein ...
Learn which Dividend Aristocrats ETF charges the lowest fees and how that can impact long-term performance. We compare expense ratios and help you choose smarter.
27,457 articlesA major biotech fund has increased its stake in Scholar Rock, increasing exposure to a platform that targets protein ...
A clear, practical look at Bowhead Specialty's Q4 2025 earnings transcript. Learn what the numbers mean, which metric...
New findings from a McKinsey study identify 61 growth leaders that beat peers from 2019 to 2024. The report highlight...
Household bills are climbing again amid a web of factors from aging infrastructure to data-center demand. This report...
Visa and Bridge announce a global expansion of stablecoin-backed cards, moving from 18 markets to a planned 100 count...
A New York federal court ruled that firms that paid emergency tariffs later deemed unlawful may seek refunds. The dec...
A bold, high‑risk biotech bet can pay off with patience and discipline. This article breaks down iovance biotherapeut...
This millionaire interview digs into how a couple turned disciplined saving into a multi-million portfolio. Learn act...
IonQ posted full-year revenue of $130 million and a 2026 guidance of $225-245 million, as it leans on defense contrac...
Oil prices climb amid geopolitical risk, reviving questions about fuel costs and EV demand. tesla (tsla) prices rise ...
The economy isn’t one size fits all. While stock markets soar, the middle class often feels squeezed. This guide expl...
Is a stock market crash 2026? on the horizon. This guide translates fear into a concrete action plan—emergency funds,...